These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1034 related items for PubMed ID: 24710123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F.
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [Abstract] [Full Text] [Related]

  • 7. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.
    Lung Cancer; 2015 Jan 05; 87(1):23-7. PubMed ID: 25468149
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C, Guler OC, Reyhan M, Yapar AF.
    Gynecol Oncol; 2015 Apr 01; 137(1):40-6. PubMed ID: 25641567
    [Abstract] [Full Text] [Related]

  • 14. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
    Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S, Stamatis G, Friedel G, Darwiche K, Jöckel KH, Eberhardt W, Stuschke M.
    J Clin Oncol; 2016 Jul 20; 34(21):2526-33. PubMed ID: 27247220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
    Oh D, Ahn YC, Park HC, Lim DH, Noh JM, Cho WK, Pyo H.
    Oncotarget; 2017 May 30; 8(22):35700-35706. PubMed ID: 28415687
    [Abstract] [Full Text] [Related]

  • 18. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.
    Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC.
    Oral Oncol; 2013 Mar 30; 49(3):261-8. PubMed ID: 23036774
    [Abstract] [Full Text] [Related]

  • 19. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N, Liang R, Gensheimer MF, Guo M, Zhu H, Yu J, Diehn M, Loo BW, Li R, Wu J.
    Theranostics; 2020 Mar 30; 10(25):11707-11718. PubMed ID: 33052242
    [Abstract] [Full Text] [Related]

  • 20. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
    Guler OC, Torun N, Yildirim BA, Onal C.
    Br J Radiol; 2018 Apr 30; 91(1084):20170552. PubMed ID: 29293366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.